61 related articles for article (PubMed ID: 24069261)
1. Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
Freiburghaus C; Emruli VK; Johansson A; Eskelund CW; Grønbæk K; Olsson R; Ek F; Jerkeman M; Ek S
BMC Cancer; 2018 Apr; 18(1):466. PubMed ID: 29695239
[TBL] [Abstract][Full Text] [Related]
2. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.
Yi S; Yan Y; Jin M; Bhattacharya S; Wang Y; Wu Y; Yang L; Gine E; Clot G; Chen L; Yu Y; Zou D; Wang J; Phan AT; Cui R; Li F; Sun Q; Zhai Q; Wang T; Yu Z; Liu L; Liu W; Lyv R; Sui W; Huang W; Xiong W; Wang H; Li C; Xiao Z; Hao M; Wang J; Cheng T; Bea S; Herrera AF; Danilov A; Campo E; Ngo VN; Qiu L; Wang L
J Clin Invest; 2024 May; 134(10):. PubMed ID: 38747295
[No Abstract] [Full Text] [Related]
3. Tet3-mediated hydroxymethylation of epigenetically silenced genes contributes to bone morphogenic protein 7-induced reversal of kidney fibrosis.
Tampe B; Tampe D; Müller CA; Sugimoto H; LeBleu V; Xu X; Müller GA; Zeisberg EM; Kalluri R; Zeisberg M
J Am Soc Nephrol; 2014 May; 25(5):905-12. PubMed ID: 24480825
[TBL] [Abstract][Full Text] [Related]
4. High BMP7 expression is associated with poor prognosis in ovarian cancer.
Vasan R; Yadav J; Aiyappa-Maudsley R; Deen S; Storr SJ; Martin SG
J Cell Mol Med; 2023 Nov; 27(21):3378-3387. PubMed ID: 37688374
[TBL] [Abstract][Full Text] [Related]
5. Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years.
Ehata S; Miyazono K
Front Cell Dev Biol; 2022; 10():883523. PubMed ID: 35693928
[TBL] [Abstract][Full Text] [Related]
6. The deubiquitinating enzyme PSMD14 facilitates tumor growth and chemoresistance through stabilizing the ALK2 receptor in the initiation of BMP6 signaling pathway.
Seo D; Jung SM; Park JS; Lee J; Ha J; Kim M; Park SH
EBioMedicine; 2019 Nov; 49():55-71. PubMed ID: 31685442
[TBL] [Abstract][Full Text] [Related]
7. Expression Of BMP7 In Ovarian Cancer And Biological Effect Of BMP7 Knockdown On Ovarian Cancer Cells.
Guan H; Li J; Sun R; Liu W; Feng M; Ma H; Li C
Onco Targets Ther; 2019; 12():7897-7909. PubMed ID: 31576147
[TBL] [Abstract][Full Text] [Related]
8. BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF-β receptor type I ALK5.
Bollum LK; Huse K; Oksvold MP; Bai B; Hilden VI; Forfang L; Yoon SO; Wälchli S; Smeland EB; Myklebust JH
PLoS One; 2017; 12(5):e0177188. PubMed ID: 28489883
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for etiology and prognosis of mantle cell lymphoma.
Wang Y; Ma S
Expert Rev Hematol; 2014 Apr; 7(2):233-43. PubMed ID: 24559208
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib in mantle cell lymphoma.
Suh KS; Goy A
Future Oncol; 2008 Apr; 4(2):149-68. PubMed ID: 18407730
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
12. BMP7 expression correlates with secondary drug resistance in mantle cell lymphoma.
Camara-Clayette V; Koscielny S; Roux S; Lamy T; Bosq J; Bernard M; Fest T; Lazar V; Lenoir G; Ribrag V
PLoS One; 2013; 8(9):e73993. PubMed ID: 24069261
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Pérez-Galán P; Mora-Jensen H; Weniger MA; Shaffer AL; Rizzatti EG; Chapman CM; Mo CC; Stennett LS; Rader C; Liu P; Raghavachari N; Stetler-Stevenson M; Yuan C; Pittaluga S; Maric I; Dunleavy KM; Wilson WH; Staudt LM; Wiestner A
Blood; 2011 Jan; 117(2):542-52. PubMed ID: 20956803
[TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
[TBL] [Abstract][Full Text] [Related]
15. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Weigert O; Pastore A; Rieken M; Lang N; Hiddemann W; Dreyling M
Leukemia; 2007 Mar; 21(3):524-8. PubMed ID: 17268531
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
